Status: Recruiting
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Participants needed: 74
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: PharmaINUpdated: Sep 5, 2025Locations: 9
Eligibility criteria
History of cirrhosis based on histology or a combination of clinical, radiologic... [+3]
Significant abnormalities in medical history or on physical examination, includi... [+7]